Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,325

Glucagon-like peptide-1 7–36: a physiological incretin in man

Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651

Reduced incretin effect in Type 2 (non-insulin dependent) diabetes

Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092

Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans

Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 916

Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 885

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792

Glucagon-Like Peptide-1-(7–36)Amide Is Transformed to Glucagon-Like Peptide-1-(9–36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine1

Hansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595

Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling

Thompson, K. A. (2013) · Clinical and Experimental Pharmacology · doi:10.4172/2161-1459.1000138 · Cited by 36

Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets

Folli, F. B., Finzi, G., Manfrini, R., Galli, A., Casiraghi, F., Centofanti, L., Berra, C., Fiorina, P., Davalli, A. M., Rosa, S. L., et al. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00236.2023 · Cited by 32

A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus

Seino, Y., Inagaki, N., Miyahara, H., Okuda, I., Bush, M., Ye, J., Holland, M. C., JOHNSON, S. L., Lewis, E., & Nakajima, H. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.896327 · Cited by 31

Once weekly exenatide: efficacy, tolerability and place in therapy

Wysham, C., Grimm, M. F., & Chen, S. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12084 · Cited by 31

Peptide Therapeutics: it‘s All in the Delivery

GRANT, M. L., & Leone‐Bay, A. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.79 · Cited by 30

Comparison of liraglutide versus other incretin‐related anti‐hyperglycaemic agents

Blonde, L., & Montanya, E. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01575.x · Cited by 31

Glucagon-like peptide 1 (GLP-1) and metabolic diseases

Rotella, C. M., Pala, L., & Mannucci, E. (2005) · Journal of Endocrinological Investigation · doi:10.1007/bf03347560 · Cited by 31

Long-acting parenteral formulations of hydrophilic drugs, proteins, and peptide therapeutics: mechanisms, challenges, and therapeutic benefits with a focus on technologies

Nakmode, D. D., Singh, B., Abdella, S., Song, Y., & Garg, S. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01747-y · Cited by 30

Non‐glycaemic effects mediated via GLP‐1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide

Vilsbøll, T., & Garber, A. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01579.x · Cited by 30

Ezetimibe Stimulates Intestinal Glucagon-Like Peptide 1 Secretion Via the MEK/ERK Pathway Rather Than Dipeptidyl Peptidase 4 Inhibition

Chang, E., Kim, L., Choi, J. M., Park, S. E., Rhee, E., Lee, W., Oh, K.-W., Park, S., Park, D. I., & Park, C. (2015) · Metabolism · doi:10.1016/j.metabol.2015.02.001 · Cited by 29

The Multiple Faces of Glucagon-Like Peptide-1—Obesity, Appetite, and Stress: What Is Next? A Review

Frezza, E. E., Wachtel, M. S., & Chiriva‐Internati, M. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9096-2 · Cited by 29

Gut peptides in the treatment of diabetes mellitus

Vahl, T. P., & D’Alessio, D. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.3.177 · Cited by 29

Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus

Nisal, K., Kela, R., Khunti, K., & Davies, M. J. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-152 · Cited by 28

Incretin therapy for diabetes mellitus type 2

Holst, J. J. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000516 · Cited by 29

Conjugates for use in peptide therapeutics: A systematic review and meta-analysis

Wijesinghe, A., Kumari, S., & Booth, V. K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0255753 · Cited by 28

Hepatocyte-specific HIF-1α ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation

Lee, Y. S., Riopel, M., Cabrales, P., & Bandyopadhyay, G. K. (2019) · Science Advances · doi:10.1126/sciadv.aaw4176 · Cited by 30

Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model

Fang, X., Du, Z., Duan, C., Zhan, S., Wang, T., Zhu, M., Shi, J., Meng, J., Zhang, X., Yang, M., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118966 · Cited by 29

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 secretion in humans: Characteristics and regulation

Alsalim, W., Lindgren, O., & Åhrén, B. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13962 · Cited by 30

Impact of Glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: A narrative review

Liarakos, A. L., Tentolouris, A., Kokkinos, A. D., Eleftheriadou, I., & Tentolouris, N. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108390 · Cited by 27

Exenatide: a novel treatment of Type 2 diabetes

Åhrén, B. (2005) · Therapy · doi:10.2217/14750708.2.2.207 · Cited by 26

Glucagon-like peptide-1: physiology and therapeutic potential

Holst, J. J. (2005) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000151395.52819.47 · Cited by 27

The Physiology of Incretin Hormones and the Basis for DPP-4 Inhibitors

McKennon, S., & Campbell, R. K. (2007) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721706297451 · Cited by 27

Emerging GLP-1 receptor agonists

Lund, A., Knop, F. K., & Vilsbøll, T. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.616493 · Cited by 27

Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats

Akarte, A. S., Srinivasan, B. P., Gandhi, S., & Sole, S. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.07.003 · Cited by 26

Emerging role of GLP-1 receptor agonists in the treatment of obesity

Neff, L. M. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s6816 · Cited by 31

The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1

Plamboeck, A., Veedfald, S., Deacon, C. F., Hartmann, B., Vilsbøll, T., Knop, F. K., & Holst, J. J. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00123.2015 · Cited by 24

Metabolism of glucagon-like peptide-2 in pigs: Role of dipeptidyl peptidase IV

Hansen, L., Hare, K. J., Hartmann, B., Deacon, C. F., Ugleholdt, R., Plamboeck, A., & Holst, J. J. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.08.012 · Cited by 25

Liraglutide for the Treatment of Type 2 Diabetes

Peters, K. R. (2011) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3182204c16 · Cited by 25

Recombinant Peptide Production Platform Coupled with Site-Specific Albumin Conjugation Enables a Convenient Production of Long-Acting Therapeutic Peptide

Bak, M., Park, J., Min, K., Cho, J., Seong, J., Hahn, Y. S., Tae, G., & Kwon, I. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12040364 · Cited by 24

Long-Acting GLP-1 Analogs for the Treatment of Type 2 Diabetes Mellitus

Vilsbøll, T., & Knop, F. K. (2008) · BioDrugs · doi:10.2165/00063030-200822040-00004 · Cited by 25

Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data

Anastasiou, I. A., Argyrakopoulou, G., Dalamaga, Μ., & Kokkinos, A. D. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00623-1 · Cited by 28

Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon

Sekar, R., Singh, K., Arokiaraj, A. W. R., & Chow, B. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.05.002 · Cited by 26

The spectrum of antidiabetic actions of GLP-1 in patients with diabetes

Vilsbøll, T., Holst, J. J., & Knop, F. K. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.011 · Cited by 23

Antidiabetic Effects of Omega-3 Polyunsaturated Fatty Acids: From Mechanism to Therapeutic Possibilities

Iwase, Y., Kamei, N., & Takeda‐Morishita, M. (2015) · Pharmacology & Pharmacy · doi:10.4236/pp.2015.63020 · Cited by 25

Sitagliptin: A novel agent for the management of type 2 diabetes mellitus

Pham, D. Q., Nogid, A., & Plakogiannis, R. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070248 · Cited by 25

Gastrointestinal Hormones and Neurotransmitters

Liddle, R. A. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6189-2.00001-9 · Cited by 24

Effects of GLP‐1 Receptor Agonists in Alcohol Use Disorder

Klausen, M. K., Knudsen, G. M., Vilsbøll, T., & Fink‐Jensen, A. (2025) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70004 · Cited by 26

Fasting plasma peptide-YY concentrations are elevated but do not rise postprandially in type 2 diabetes

English, P., Ashcroft, A., Patterson, M., Dovey, T. M., Halford, J. C. G., Harrison, J., Eccleston, D., Bloom, S. R., Ghatei, M. A., & Wilding, J. P. H. (2006) · Diabetologia · doi:10.1007/s00125-006-0344-y · Cited by 23

Therapeutic Fusion Proteins

Marsh, M. C., & Owen, S. C. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00873-8 · Cited by 27

Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?

Giugliano, D., Standl, E., Vilsbøll, T., Betteridge, J. D., Bonadonna, R. C., Campbell, I. W., Schernthaner, G.-H., Staels, B., Trichopoulou, A., & Farinaro, E. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0134-3 · Cited by 23

Structure based virtual screening of MDPI database: Discovery of structurally diverse and novel DPP-IV inhibitors

Tanwar, O., Tanwar, L., Shaquiquzzaman, M., Alam, M. M., & Akhter, M. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.05.076 · Cited by 23

Albiglutide: a unique GLP-1 receptor agonist

Rendell, M. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1240780 · Cited by 24

Pharmacokinetic/Pharmacodynamic Modeling of GLP-1 in Healthy Rats

Cao, Y., Gao, W., & Jusko, W. J. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0652-x · Cited by 22

Exenatide: A Novel Approach for Treatment of Type 2 Diabetes

Mikhail, N. E. (2006) · Southern Medical Journal · doi:10.1097/01.smj.0000240730.86237.b6 · Cited by 21

Appetite and Hedonism: Gut Hormones and the Brain

Simpson, K. A., & Bloom, S. R. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.08.001 · Cited by 21

Macrocarpal C isolated from Eucalyptus globulus inhibits dipeptidyl peptidase 4 in an aggregated form

Kato, E., Kawakami, K., & Kawabata, J. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2017.1396458 · Cited by 21

Liraglutide for treating type 1 diabetes

Dejgaard, T. F., Frandsen, C. S., Holst, J. J., & Madsbad, S. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1160050 · Cited by 21

Impaired circulating glucagon‐like peptide‐1 response to oral glucose in women with previous gestational diabetes

Forbes, S., Moonan, M., Robinson, S., Anyaoku, V., Patterson, M., Murphy, K. G., Ghatei, M. A., Bloom, S. R., & Johnston, D. G. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02172.x · Cited by 21

Glucagon‐like peptide‐1: Are its roles as endogenous hormone and therapeutic wizard congruent?

Holst, J. J. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13433 · Cited by 20

Exendin-4 promotes retinal ganglion cell survival and function by inhibiting calcium channels in experimental diabetes

Wang, Y., Wang, L., Shao, Y., Weng, S.-J., Yang, X., & Zhong, Y. (2023) · iScience · doi:10.1016/j.isci.2023.107680 · Cited by 23

Intermittent Use of a Short-Course Glucagon-like Peptide-1 Receptor Agonist Therapy Limits Adverse Cardiac Remodeling via Parkin-dependent Mitochondrial Turnover

Germano, J. D. F., Huang, C., Sin, J., Song, Y., Tucker, K. C., Taylor, D. J. R., Saadaeijahromi, H., Stotland, A. B., Piplani, H., Gottlieb, R. A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-64924-2 · Cited by 20

Pharmacological profile of once-weekly injectable semaglutide for chronic weight management

Lau, D. C. W., Batterham, R. L., & le Roux, C. W. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2070473 · Cited by 24

Evidence connecting old, new and neglected glucose‐lowering drugs to bile acid‐induced GLP ‐1 secretion: A review

Kårhus, M. L., Brønden, A., Sonne, D. P., Vilsbøll, T., & Knop, F. K. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12946 · Cited by 20

Comparative Transcriptome Analysis Reveals That Exendin-4 Improves Steatosis in HepG2 Cells by Modulating Signaling Pathways Related to Lipid Metabolism

Errafii, K., Khalifa, O., Al-Akl, N. S., & Arredouani, A. (2022) · Biomedicines · doi:10.3390/biomedicines10051020 · Cited by 17

Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations

Tanwar, O., Deora, G. S., Tanwar, L., Kumar, G., Janardhan, S., Alam, M. M., Shaquiquzzaman, M., & Akhter, M. (2014) · Journal of Molecular Modeling · doi:10.1007/s00894-014-2118-7 · Cited by 18

Clinical Studies of Liraglutide, a Novel, Once‐Daily Human Glucagon‐Like Peptide‐1 Analog for Improved Management of Type 2 Diabetes Mellitus

Drab, S. R. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.pt2.43s · Cited by 18

Evaluation of novel particles as an inhalation system for GLP‐1

Leone‐Bay, A., GRANT, M. L., Greene, S. F., Stowell, G. W., Daniels, S., Smithson, A., Villanueva, S., Cope, S., Carrera, K., Reyes, S., et al. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01096.x · Cited by 18

An Ultrasensitive UPLC–MS/MS Assay for the Quantification of the Therapeutic Peptide Liraglutide in Plasma to Assess the Oral and Nasal Bioavailability in Beagle Dogs

Sauter, M., Uhl, P., Majewsky, M., Fresnais, M., Haefeli, W. E., & Burhenne, J. (2019) · Bioanalysis · doi:10.4155/bio-2018-0322 · Cited by 18

Genetic variation in lean body mass, changes of appetite and weight loss in response to diet interventions: The POUNDS Lost trial

Li, X., Zhou, T., Ma, H., Heianza, Y., Champagne, C. M., Williamson, D. A., Bray, G. A., Sacks, F. M., & Qi, L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14155 · Cited by 19

Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics

Perfetti, R. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0250 · Cited by 18

Dipeptidyl-peptidase IV

Misumi, Y., & Ikehara, Y. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382219-2.00745-6 · Cited by 18

Preliminary Study Characterizing the Use of Sitagliptin for Glycemic Control in Healthy Beagle Dogs with Normal Gluco-Homeostasis

Oda, H., Mori, A., Peter, L. E. E., Saeki, K., Arai, T., & Sako, T. (2014) · Journal of Veterinary Medical Science · doi:10.1292/jvms.13-0590 · Cited by 17

Design and Development of a New Glucagon-Like Peptide-1 Receptor Agonist to Obtain High Oral Bioavailability

Chen, H., Lu, Y., Shi, S., Zhang, Q., Cao, X., Sun, L., An, D., Zhang, X., Kong, X., & Liu, J. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03265-3 · Cited by 18

Acute but not chronic activation of brain glucagon‐like peptide‐1 receptors enhances glucose‐stimulated insulin secretion in mice

Tudurí, E., Beiroa, D., Porteiro, B., López, M., Diéguez, C., & Nogueiras, R. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12488 · Cited by 17

GLP-1 mimetic drugs and the risk of exocrine pancreatic disease: Cell and animal studies

Williams, J. A. (2015) · Pancreatology · doi:10.1016/j.pan.2015.11.008 · Cited by 18

Glucolipotoxicity and GLP-1 secretion

Hong, J.-H., Kim, D., & Lee, M. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001905 · Cited by 17

Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test

Møller, J. B., Jusko, W. J., Gao, W., Hansen, T. F., Pedersen, O. B., Holst, J. J., Overgaard, R. V., Madsen, H., & Ingwersen, S. H. (2011) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-011-9216-2 · Cited by 17

GLP-1 Receptor Mediated Targeting of a Fluorescent Zn2+ Sensor to Beta Cell Surface for Imaging Insulin/Zn2+ Release

Li, D., Huang, Z., Chen, S., Hu, Z., & Li, W.-H. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00332 · Cited by 17

Enhanced plasma half-life and efficacy of engineered human albumin-fused GLP-1 despite enzymatic cleavage of its C-terminal end

Nilsen, J., Aaen, K. H., Benjakul, S., Ruso‐Julve, F., Greiner, T. U., Bejan, D., Stensland, M., Singh, S. K., Schlothauer, T., Sandlie, I., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08249-8 · Cited by 21

Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently

Cheong, Y.-H., Kim, M.-K., Son, M.-H., & Kaang, B. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.12.004 · Cited by 17

The incretin system and cardiometabolic disease

Szmitko, P. E., Leiter, L. A., & Verma, S. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)70010-6 · Cited by 17

A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite

Albrechtsen, N. J. W., Asmar, A., Jensen, F. H., Toräng, S., Simonsen, L., Kuhre, R. E., Asmar, M., Veedfald, S., Plamboeck, A., Knop, F. K., et al. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00005.2017 · Cited by 15

New Glucose-Lowering Agents for Diabetic Kidney Disease

de Vos, L. C., Hettige, T., & Cooper, M. E. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2018.01.002 · Cited by 16

Glycosaminoglycan Conjugation for Improving the Duration of Therapeutic Action of Glucagon-Like Peptide-1

Ichikawa, M., Hirayama, T., Fukushima, M., Kitazawa, I., Kojima, K., Sakai, T., Takatsu, Y., & Ohtaki, T. (2018) · ACS Omega · doi:10.1021/acsomega.8b00467 · Cited by 16

Design of chimeric GLP-1A using oligomeric bile acids to utilize transporter-mediated endocytosis for oral delivery

Kweon, S., Lee, J.-H., Yang, S.-B., Park, S. J., Subedi, L., Shim, J., Cho, S., Choi, J. U., Byun, Y., Park, J., et al. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00421-7 · Cited by 15

Incretin therapy and its effect on body weight in patients with diabetes

Lind, M. (2012) · Primary care diabetes · doi:10.1016/j.pcd.2012.04.006 · Cited by 15

Incretins and the intensivist: what are they and what does an intensivist need to know about them?

Plummer, M. P., Chapman, M. J., Horowitz, M., & Deane, A. M. (2014) · Critical Care · doi:10.1186/cc13737 · Cited by 17

Review: DPP IV inhibitors - current evidence and future directions

Vilsbøll, T., & Knop, F. K. (2007) · The British Journal of Diabetes · doi:10.1177/14746514070070020401 · Cited by 16

Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes

Prato, S. D. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01439.x · Cited by 15

The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management

Roges, O. A., Baron, M., & Philis‐Tsimikas, A. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.705 · Cited by 15

Pancreatic beta‐cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes

Moon, J. H., Choe, H. J., & Lim, S. K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14221 · Cited by 13

Effect of Short-Term Increase in Meal Frequency on Glucose Metabolism in Individuals with Normal Glucose Tolerance or Impaired Fasting Glucose: A Randomized Crossover Clinical Trial

Hibi, M., Hari, S., Yamaguchi, T. F., Mitsui, Y., Kondo, S., & Katashima, M. (2019) · Nutrients · doi:10.3390/nu11092126 · Cited by 17

Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.

Hare, K. J. (2010) · PubMed · Cited by 14

Incretin hormones and beta cell function in chronic pancreatitis.

Knop, F. K. (2010) · PubMed · Cited by 14

Injectable Biodegradable Silica Depot: Two Months of Sustained Release of the Blood Glucose Lowering Peptide, Pramlintide

Tyagi, P., Koskinen, M., Mikkola, J. H., Sarkhel, S., Leino, L., Seth, A., Madalli, S., Will, S., HOWARD, V. G., Brant, H., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030553 · Cited by 13

Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial)

Klausen, M. K., Kuzey, T., Pedersen, J. N., Justesen, S. K., Rasmussen, L. J. H., Knorr, U., Mason, G. F., Ekstrøm, C. T., Holst, J. J., Koob, G. F., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-086454 · Cited by 13

Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection

Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 15

Incretin‐based therapies: Therapeutic rationale and pharmacological promise for type 2 diabetes

Wick, A., & Newlin, K. (2009) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2009.00455.x · Cited by 15

Engineering PEG-fatty acid stapled, long-acting peptide agonists for G protein-coupled receptors

Lear, S., Amso, Z., & Shen, W. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.02.008 · Cited by 14

Elevated circulating fasting glucagon-like peptide-1 in surgical patients with aortic valve disease and diabetes

Krizhanovskii, C., Ntika, S., Olsson, C., Eriksson, P. O., & Franco‐Cereceda, A. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0279-0 · Cited by 13

Glucagon‐like peptide‐1‐based therapies: new developments and emerging data

Garber, A. J. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00921.x · Cited by 14

Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight

Feetham, C. H., Ai, M., Culotta, I., Costa, A., Hunter, J., Brown, R. A., Coşkun, T., Emmerson, P. J., D’Agostino, G., & Luckman, S. M. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102214 · Cited by 12

Incretin Hormones: Mechanisms, Therapeutic Implications, and Future Directions in Glucose Regulation and Diabetes Management

Zargar, A. A., Mehta, V., Huddar, V., Gupta, R., Bhandari, K., Posa, M. K., Ramya, T. S., Snigdha, D., Vijayakumar, B., Sharma, M. C., et al. (2025) · Current Proteomics · doi:10.1016/j.curpro.2025.100014 · Cited by 15

A novel strategy for production of liraglutide precursor peptide and development of a new long-acting incretin mimic

Ahmadi, S., Shahsavani, M. B., Tavaf, Z., Albaghlany, R. M., Kumar, A., Moosavi‐Movahedi, A. A., & Yousefi, R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266833 · Cited by 13

Post-prandial secretion of glucagon-like peptide-2 (GLP-2) after carbohydrate-, fat- or protein enriched meals in healthy subjects

Prahm, A. P., Hvistendahl, M., Brandt, C. F., Blanche, P., Hartmann, B., Holst, J. J., & Jeppesen, P. B. (2023) · Peptides · doi:10.1016/j.peptides.2023.171091 · Cited by 12

Interleukin-6 CpG Methylation and Body Weight Correlate Differently in Type 2 Diabetes Patients Compared to Obese and Lean Controls

Aumueller, E., Remely, M., Baeck, H., Hippe, B., Brath, H., & Haslberger, A. G. (2015) · Lifestyle Genomics · doi:10.1159/000381714 · Cited by 13

Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

Campos, C., & Unger, J. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1971461 · Cited by 13

A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP‐1 dual agonist

Bosch, R., Petrone, M., Arends, R., Vicini, P., Sijbrands, E. J. G., Hoefman, S., & Snelder, N. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12752 · Cited by 11

The Effects of a GLP‐1 Analog on Glucose Homeostasis in Type 2 Diabetes Mellitus Quantified by an Integrated Glucose Insulin Model

Røge, R. M., Klim, S., Ingwersen, S., Kjellsson, M., & Kristensen, N. R. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.11 · Cited by 13

The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects

Vilsbøll, T., Agersø, H., Lauritsen, T. L. B., Deacon, C. F., Aaboe, K., Madsbad, S., Krarup, T., & Holst, J. J. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.07.007 · Cited by 75

Glucagon‐like peptide (GLP)‐1 and leptin concentrations in obese patients with Type 2 diabetes mellitus

Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Fanelli, A., Messeri, G., & Rotella, C. M. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00367.x · Cited by 106

Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetologia · doi:10.1007/s00125-013-2841-0 · Cited by 251

Antidiabetogenic action of glucagon‐like peptide‐1 related to administration relative to meal intake in subjects with type 2 diabetes

Gutniak, M., Svartberg, J. B., Hellström, P. M., Holst, J. J., Adner, N., & Åhrén, B. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00862.x · Cited by 27

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369